Avacta Group, the developer of Affimer biotherapeutics and reagents, provided an update on the Affimer therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas. Avacta has generated a large number of Affimer proteins that bind to the first…
Optibrium collaborates with Enamine and BioSolveIT to add REAL Space Search Tool to StarDrop
Optibrium™, BioSolveIT™ and Enamine™, providers of software and services for drug discovery, today announce a three-way collaboration enabling efficient search of Enamine’s REAL Space directly from within Optibrium’s StarDrop™ software. This extension to StarDrop is powered by BioSolveIT’s proprietary Feature Trees (FTrees) technology, to search a gigantic chemical space of over 11 billion readily accessible…
LUNAC Therapeutics develops the next generation anticoagulants and announces fundings
LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the identification and development of advanced anticoagulants with minimal bleeding risk, today announced it has spun out of the University of Leeds with £2.65M funding in the first close of a Series A financing round. The investment is being led by Epidarex Capital and…
Turbine secures €3 million EUR seed fund to expand the potential of simulation-first drug discovery
Turbine, a simulation-based drug discovery company today announced the closing of an institutional financing round led by Delin Ventures. The seed fund will be used to redesign the failure-prone oncology drug discovery process into a series of rational steps facilitated by Turbine’s proprietary human cell model and simulation platform. The company’s first institutional financing round…